BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Elfiky AA. Zika viral polymerase inhibition using anti-HCV drugs both in market and under clinical trials. J Med Virol 2016;88:2044-51. [PMID: 27604059 DOI: 10.1002/jmv.24678] [Cited by in Crossref: 49] [Cited by in F6Publishing: 51] [Article Influence: 8.2] [Reference Citation Analysis]
Number Citing Articles
1 Elfiky AA. Novel guanosine derivatives against Zika virus polymerase in silico. J Med Virol 2020;92:11-6. [PMID: 31436327 DOI: 10.1002/jmv.25573] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
2 Elfiky AA. Novel Guanosine Derivatives as Anti-HCV NS5b Polymerase: A QSAR and Molecular Docking Study. Med Chem 2019;15:130-7. [PMID: 30324891 DOI: 10.2174/1573406414666181015152511] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 4.0] [Reference Citation Analysis]
3 Gorgulla C, Fackeldey K, Wagner G, Arthanari H. Accounting of Receptor Flexibility in Ultra-Large Virtual Screens with VirtualFlow Using a Grey Wolf Optimization Method. Supercomput Front Innov 2020;7:4-12. [PMID: 34693068 DOI: 10.14529/jsfi200301] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
4 Singh A, Jana NK. Discovery of potential Zika virus RNA polymerase inhibitors by docking-based virtual screening. Computational Biology and Chemistry 2017;71:144-51. [DOI: 10.1016/j.compbiolchem.2017.10.007] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 2.4] [Reference Citation Analysis]
5 Bharti R, Shukla SK. Molecules against Covid-19: An in silico approach for drug development. Journal of Electronic Science and Technology 2021;19:100095. [DOI: 10.1016/j.jnlest.2021.100095] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
6 Aftab SO, Ghouri MZ, Masood MU, Haider Z, Khan Z, Ahmad A, Munawar N. Analysis of SARS-CoV-2 RNA-dependent RNA polymerase as a potential therapeutic drug target using a computational approach. J Transl Med 2020;18:275. [PMID: 32635935 DOI: 10.1186/s12967-020-02439-0] [Cited by in Crossref: 45] [Cited by in F6Publishing: 41] [Article Influence: 22.5] [Reference Citation Analysis]
7 Ismail AM, Elfiky AA, Elshemey WM. Recognition of the gluconeogenic enzyme, Pck1, via the Gid4 E3 ligase: An in silico perspective. J Mol Recognit 2019;33. [DOI: 10.1002/jmr.2821] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
8 Sharma D, Kunamneni A. Recent progress in the repurposing of drugs/molecules for the management of COVID-19. Expert Rev Anti Infect Ther 2021;19:889-97. [PMID: 33270490 DOI: 10.1080/14787210.2021.1860020] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
9 Basile K, Kok J, Dwyer DE. Zika virus: what, where from and where to? Pathology 2017;49:698-706. [PMID: 29050846 DOI: 10.1016/j.pathol.2017.08.002] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 3.4] [Reference Citation Analysis]
10 Dhankhar P, Dalal V, Kumar V. Screening of Severe Acute Respiratory Syndrome Coronavirus 2 RNA-Dependent RNA Polymerase Inhibitors Using Computational Approach. J Comput Biol 2021;28:1228-47. [PMID: 34847746 DOI: 10.1089/cmb.2020.0639] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Wilder-Smith A, Vannice K, Durbin A, Hombach J, Thomas SJ, Thevarjan I, Simmons CP. Zika vaccines and therapeutics: landscape analysis and challenges ahead. BMC Med 2018;16:84. [PMID: 29871628 DOI: 10.1186/s12916-018-1067-x] [Cited by in Crossref: 48] [Cited by in F6Publishing: 36] [Article Influence: 12.0] [Reference Citation Analysis]
12 Elfiky AA. Zika virus: novel guanosine derivatives revealed strong binding and possible inhibition of the polymerase. Future Virology 2017;12:721-8. [DOI: 10.2217/fvl-2017-0081] [Cited by in Crossref: 16] [Cited by in F6Publishing: 9] [Article Influence: 3.2] [Reference Citation Analysis]
13 Faheem, Kumar BK, Sekhar KVGC, Kunjiappan S, Jamalis J, Balaña-Fouce R, Tekwani BL, Sankaranarayanan M. Druggable targets of SARS-CoV-2 and treatment opportunities for COVID-19. Bioorg Chem 2020;104:104269. [PMID: 32947136 DOI: 10.1016/j.bioorg.2020.104269] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 8.5] [Reference Citation Analysis]
14 Nimgampalle M, Devanathan V, Saxena A. Screening of Chloroquine, Hydroxychloroquine and its derivatives for their binding affinity to multiple SARS-CoV-2 protein drug targets. J Biomol Struct Dyn 2021;39:4949-61. [PMID: 32579059 DOI: 10.1080/07391102.2020.1782265] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
15 Reznik SE, Ashby CR Jr. Sofosbuvir: an antiviral drug with potential efficacy against Zika infection. Int J Infect Dis 2017;55:29-30. [PMID: 27988410 DOI: 10.1016/j.ijid.2016.12.011] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 3.7] [Reference Citation Analysis]
16 Sinigaglia A, Riccetti S, Trevisan M, Barzon L. In silico approaches to Zika virus drug discovery. Expert Opin Drug Discov 2018;13:825-35. [PMID: 30160181 DOI: 10.1080/17460441.2018.1515909] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
17 Kumar R, Mishra S, Shreya, Maurya SK. Recent advances in the discovery of potent RNA-dependent RNA-polymerase (RdRp) inhibitors targeting viruses. RSC Med Chem 2021;12:306-20. [PMID: 34046618 DOI: 10.1039/d0md00318b] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
18 Elfiky AA, Ismail AM. Molecular docking revealed the binding of nucleotide/side inhibitors to Zika viral polymerase solved structures. SAR QSAR Environ Res 2018;29:409-18. [PMID: 29652194 DOI: 10.1080/1062936X.2018.1454981] [Cited by in Crossref: 20] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
19 Calmels C, Ventura M, Aknin C, Métifiot M, Andreola ML. De novo RNA synthesis catalyzed by the Zika Virus RNA polymerase domain. Sci Rep 2017;7:2697. [PMID: 28577343 DOI: 10.1038/s41598-017-03038-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
20 Elfiky AA. Anti-HCV, nucleotide inhibitors, repurposing against COVID-19. Life Sci. 2020;248:117477. [PMID: 32119961 DOI: 10.1016/j.lfs.2020.117477] [Cited by in Crossref: 305] [Cited by in F6Publishing: 290] [Article Influence: 152.5] [Reference Citation Analysis]
21 Pirzada RH, Haseeb M, Batool M, Kim M, Choi S. Remdesivir and Ledipasvir among the FDA-Approved Antiviral Drugs Have Potential to Inhibit SARS-CoV-2 Replication. Cells 2021;10:1052. [PMID: 33946869 DOI: 10.3390/cells10051052] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
22 Upadhyay AK, Cyr M, Longenecker K, Tripathi R, Sun C, Kempf DJ. Crystal structure of full-length Zika virus NS5 protein reveals a conformation similar to Japanese encephalitis virus NS5. Acta Crystallogr F Struct Biol Commun 2017;73:116-22. [PMID: 28291746 DOI: 10.1107/S2053230X17001601] [Cited by in Crossref: 58] [Cited by in F6Publishing: 35] [Article Influence: 11.6] [Reference Citation Analysis]
23 Ghosh AK, Brindisi M, Shahabi D, Chapman ME, Mesecar AD. Drug Development and Medicinal Chemistry Efforts toward SARS-Coronavirus and Covid-19 Therapeutics. ChemMedChem 2020;15:907-32. [PMID: 32324951 DOI: 10.1002/cmdc.202000223] [Cited by in Crossref: 105] [Cited by in F6Publishing: 84] [Article Influence: 52.5] [Reference Citation Analysis]
24 Elfiky AA, Ismail A. Molecular dynamics and docking reveal the potency of novel GTP derivatives against RNA dependent RNA polymerase of genotype 4a HCV. Life Sci 2019;238:116958. [PMID: 31628915 DOI: 10.1016/j.lfs.2019.116958] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 5.7] [Reference Citation Analysis]
25 Sacramento CQ, de Melo GR, de Freitas CS, Rocha N, Hoelz LV, Miranda M, Fintelman-Rodrigues N, Marttorelli A, Ferreira AC, Barbosa-Lima G, Abrantes JL, Vieira YR, Bastos MM, de Mello Volotão E, Nunes EP, Tschoeke DA, Leomil L, Loiola EC, Trindade P, Rehen SK, Bozza FA, Bozza PT, Boechat N, Thompson FL, de Filippis AM, Brüning K, Souza TM. The clinically approved antiviral drug sofosbuvir inhibits Zika virus replication. Sci Rep 2017;7:40920. [PMID: 28098253 DOI: 10.1038/srep40920] [Cited by in Crossref: 119] [Cited by in F6Publishing: 108] [Article Influence: 23.8] [Reference Citation Analysis]
26 Rofeal M, El-Malek FA. Ribosomal proteins as a possible tool for blocking SARS-COV 2 virus replication for a potential prospective treatment. Med Hypotheses 2020;143:109904. [PMID: 32502901 DOI: 10.1016/j.mehy.2020.109904] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
27 Aftab SO, Ghouri MZ, Masood MU, Haider Z, Khan Z, Ahmad A, Munawar N. Analysis of SARS-CoV-2 RNA-dependent RNA polymerase as a potential therapeutic drug target using a computational approach. J Transl Med 2020;18. [DOI: 10.1186/s12967-020-02439-0] [Reference Citation Analysis]
28 Elfiky AA, Ismail AM. Molecular modeling and docking revealed superiority of IDX-184 as HCV polymerase inhibitor. Future Virology 2017;12:339-47. [DOI: 10.2217/fvl-2017-0027] [Cited by in Crossref: 9] [Cited by in F6Publishing: 2] [Article Influence: 1.8] [Reference Citation Analysis]
29 Adachi K, Nielsen-Saines K. Zika clinical updates: implications for pediatrics. Curr Opin Pediatr 2018;30:105-16. [PMID: 29176498 DOI: 10.1097/MOP.0000000000000582] [Cited by in Crossref: 19] [Cited by in F6Publishing: 6] [Article Influence: 4.8] [Reference Citation Analysis]
30 Phillips MA, Stewart MA, Woodling DL, Xie Z. Has Molecular Docking Ever Brought us a Medicine? In: Vlachakis DP, editor. Molecular Docking. InTech; 2018. [DOI: 10.5772/intechopen.72898] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
31 Cao B, Parnell LA, Diamond MS, Mysorekar IU. Inhibition of autophagy limits vertical transmission of Zika virus in pregnant mice. J Exp Med 2017;214:2303-13. [PMID: 28694387 DOI: 10.1084/jem.20170957] [Cited by in Crossref: 128] [Cited by in F6Publishing: 121] [Article Influence: 25.6] [Reference Citation Analysis]
32 Karthic A, Kesarwani V, Singh RK, Yadav PK, Chaturvedi N, Chauhan P, Yadav BS, Kushwaha SK. Computational Analysis Reveals Monomethylated Triazolopyrimidine as a Novel Inhibitor of SARS-CoV-2 RNA-Dependent RNA Polymerase (RdRp). Molecules 2022;27:801. [PMID: 35164069 DOI: 10.3390/molecules27030801] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
33 Souza INO, Barros-Aragão FGQ, Frost PS, Figueiredo CP, Clarke JR. Late Neurological Consequences of Zika Virus Infection: Risk Factors and Pharmaceutical Approaches. Pharmaceuticals (Basel) 2019;12:E60. [PMID: 30999590 DOI: 10.3390/ph12020060] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 5.3] [Reference Citation Analysis]
34 Shankar A, Patil AA, Skariyachan S. Recent Perspectives on Genome, Transmission, Clinical Manifestation, Diagnosis, Therapeutic Strategies, Vaccine Developments, and Challenges of Zika Virus Research. Front Microbiol 2017;8:1761. [PMID: 28959246 DOI: 10.3389/fmicb.2017.01761] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
35 Elfiky AA. The antiviral Sofosbuvir against mucormycosis: an in silico perspective. Future Virology 2019;14:739-44. [DOI: 10.2217/fvl-2019-0076] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 2.3] [Reference Citation Analysis]
36 Chan JF, Chik KK, Yuan S, Yip CC, Zhu Z, Tee KM, Tsang JO, Chan CC, Poon VK, Lu G, Zhang AJ, Lai KK, Chan KH, Kao RY, Yuen KY. Novel antiviral activity and mechanism of bromocriptine as a Zika virus NS2B-NS3 protease inhibitor. Antiviral Res 2017;141:29-37. [PMID: 28185815 DOI: 10.1016/j.antiviral.2017.02.002] [Cited by in Crossref: 73] [Cited by in F6Publishing: 65] [Article Influence: 14.6] [Reference Citation Analysis]
37 Elfiky AA, Ibrahim IM. Zika virus envelope - heat shock protein A5 (GRP78) binding site prediction. J Biomol Struct Dyn 2021;39:5248-60. [PMID: 32579073 DOI: 10.1080/07391102.2020.1784794] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
38 Han Y, Mesplède T, Xu H, Quan Y, Wainberg MA. The antimalarial drug amodiaquine possesses anti-ZIKA virus activities. J Med Virol 2018;90:796-802. [PMID: 29315671 DOI: 10.1002/jmv.25031] [Cited by in Crossref: 31] [Cited by in F6Publishing: 26] [Article Influence: 7.8] [Reference Citation Analysis]
39 Rusanov T, Kent T, Saeed M, Hoang TM, Thomas C, Rice CM, Pomerantz RT. Identification of a Small Interface between the Methyltransferase and RNA Polymerase of NS5 that is Essential for Zika Virus Replication. Sci Rep 2018;8:17384. [PMID: 30478404 DOI: 10.1038/s41598-018-35511-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
40 Chatrin C, Talapatra SK, Canard B, Kozielski F. The structure of the binary methyltransferase-SAH complex from Zika virus reveals a novel conformation for the mechanism of mRNA capping. Oncotarget 2018;9:3160-71. [PMID: 29423037 DOI: 10.18632/oncotarget.23223] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
41 Boccuto A, Dragoni F, Picarazzi F, Lai A, Della Ventura C, Veo C, Giammarino F, Saladini F, Zehender G, Zazzi M, Mori M, Vicenti I. Sofosbuvir Selects for Drug-Resistant Amino Acid Variants in the Zika Virus RNA-Dependent RNA-Polymerase Complex In Vitro. Int J Mol Sci 2021;22:2670. [PMID: 33800884 DOI: 10.3390/ijms22052670] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
42 Pandey K, Lokhande KB, Swamy KV, Nagar S, Dake M. In Silico Exploration of Phytoconstituents From Phyllanthus emblica and Aegle marmelos as Potential Therapeutics Against SARS-CoV-2 RdRp. Bioinform Biol Insights 2021;15:11779322211027403. [PMID: 34248355 DOI: 10.1177/11779322211027403] [Reference Citation Analysis]
43 Gorshkov K, Shiryaev SA, Fertel S, Lin YW, Huang CT, Pinto A, Farhy C, Strongin AY, Zheng W, Terskikh AV. Zika Virus: Origins, Pathological Action, and Treatment Strategies. Front Microbiol 2018;9:3252. [PMID: 30666246 DOI: 10.3389/fmicb.2018.03252] [Cited by in Crossref: 23] [Cited by in F6Publishing: 16] [Article Influence: 7.7] [Reference Citation Analysis]
44 Elfiky AA. SARS-CoV-2 RNA dependent RNA polymerase (RdRp) targeting: an in silico perspective. J Biomol Struct Dyn 2021;39:3204-12. [PMID: 32338164 DOI: 10.1080/07391102.2020.1761882] [Cited by in Crossref: 70] [Cited by in F6Publishing: 89] [Article Influence: 35.0] [Reference Citation Analysis]
45 Chesnut M, Muñoz LS, Harris G, Freeman D, Gama L, Pardo CA, Pamies D. In vitro and in silico Models to Study Mosquito-Borne Flavivirus Neuropathogenesis, Prevention, and Treatment. Front Cell Infect Microbiol 2019;9:223. [PMID: 31338335 DOI: 10.3389/fcimb.2019.00223] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
46 Ferreira AC, Zaverucha-do-Valle C, Reis PA, Barbosa-Lima G, Vieira YR, Mattos M, Silva PP, Sacramento C, de Castro Faria Neto HC, Campanati L, Tanuri A, Brüning K, Bozza FA, Bozza PT, Souza TML. Sofosbuvir protects Zika virus-infected mice from mortality, preventing short- and long-term sequelae. Sci Rep 2017;7:9409. [PMID: 28842610 DOI: 10.1038/s41598-017-09797-8] [Cited by in Crossref: 67] [Cited by in F6Publishing: 54] [Article Influence: 13.4] [Reference Citation Analysis]
47 Sundar S, Piramanayagam S, Natarajan J. A review on structural genomics approach applied for drug discovery against three vector-borne viral diseases: Dengue, Chikungunya and Zika. Virus Genes 2022. [PMID: 35394596 DOI: 10.1007/s11262-022-01898-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
48 Poustforoosh A, Hashemipour H, Tüzün B, Pardakhty A, Mehrabani M, Nematollahi MH. Evaluation of potential anti-RNA-dependent RNA polymerase (RdRP) drugs against the newly emerged model of COVID-19 RdRP using computational methods. Biophys Chem 2021;272:106564. [PMID: 33711743 DOI: 10.1016/j.bpc.2021.106564] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
49 Grahl MVC, Alcará AM, Perin APA, Moro CF, Pinto ÉSM, Feltes BC, Ghilardi IM, Rodrigues FVF, Dorn M, da Costa JC, Norberto de Souza O, Ligabue-Braun R. Evaluation of drug repositioning by molecular docking of pharmaceutical resources available in the Brazilian healthcare system against SARS-CoV-2. Inform Med Unlocked 2021;23:100539. [PMID: 33623816 DOI: 10.1016/j.imu.2021.100539] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
50 Han Y, Pham HT, Xu H, Quan Y, Mesplède T. Antimalarial drugs and their metabolites are potent Zika virus inhibitors. J Med Virol 2019;91:1182-90. [PMID: 30801742 DOI: 10.1002/jmv.25440] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 7.7] [Reference Citation Analysis]
51 Elfiky AA, Elshemey WM. Molecular dynamics simulation revealed binding of nucleotide inhibitors to ZIKV polymerase over 444 nanoseconds. J Med Virol 2018;90:13-8. [PMID: 28922464 DOI: 10.1002/jmv.24934] [Cited by in Crossref: 17] [Cited by in F6Publishing: 21] [Article Influence: 3.4] [Reference Citation Analysis]
52 Elfiky AA, Mahdy SM, Elshemey WM. Quantitative structure-activity relationship and molecular docking revealed a potency of anti-hepatitis C virus drugs against human corona viruses. J Med Virol 2017;89:1040-7. [PMID: 27864902 DOI: 10.1002/jmv.24736] [Cited by in Crossref: 55] [Cited by in F6Publishing: 57] [Article Influence: 11.0] [Reference Citation Analysis]
53 Elfiky AA. Ribavirin, Remdesivir, Sofosbuvir, Galidesivir, and Tenofovir against SARS-CoV-2 RNA dependent RNA polymerase (RdRp): A molecular docking study. Life Sci. 2020;253:117592. [PMID: 32222463 DOI: 10.1016/j.lfs.2020.117592] [Cited by in Crossref: 371] [Cited by in F6Publishing: 342] [Article Influence: 185.5] [Reference Citation Analysis]
54 Ahmad Mir S, Firoz A, Alaidarous M, Alshehri B, Aziz Bin Dukhyil A, Banawas S, Alsagaby SA, Alturaiki W, Ahmad Bhat G, Kashoo F, Abdel-Hadi AM. Identification of SARS-CoV-2 RNA-dependent RNA polymerase inhibitors from the major phytochemicals of Nigella sativa: An in silico approach. Saudi J Biol Sci 2021. [PMID: 34518755 DOI: 10.1016/j.sjbs.2021.09.002] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
55 Khalid H, Landry KB, Ijaz B, Ashfaq UA, Ahmed M, Kanwal A, Froeyen M, Mirza MU. Discovery of novel Hepatitis C virus inhibitor targeting multiple allosteric sites of NS5B polymerase. Infect Genet Evol 2020;84:104371. [PMID: 32485331 DOI: 10.1016/j.meegid.2020.104371] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
56 Gan CS, Lim SK, Chee CF, Yusof R, Heh CH. Sofosbuvir as treatment against dengue? Chem Biol Drug Des 2018;91:448-55. [PMID: 28834304 DOI: 10.1111/cbdd.13091] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 3.4] [Reference Citation Analysis]